All News

DD18 Reduces Fat While Preserving Lean Mass in Mice

By Sandy Martin•November 20, 2026

In diet-induced-obese mice, D&D Pharmatech’s UCN2 agonist DD18 reduced weight and fat while lean mass was maintained or increased. The preclinical signal puts body composition—not scale weight alone—at the center of obesity drug development.

D&D Pharmatech has reported preclinical evidence that its experimental obesity drug DD18 can reduce fat while maintaining or increasing measured lean body mass in mice. A report on the ObesityWeek 2026 findings describes a stronger body-composition result when DD18 was combined with semaglutide than when the GLP-1 drug was used alone.

The findings address an increasingly important question in obesity medicine: not only how much weight a treatment helps someone lose, but what kind of tissue accounts for that change. They are also early. DD18’s evidence is currently preclinical, and a mouse lean-mass measurement cannot establish that a drug will preserve human skeletal muscle, strength or physical function.

A 30-day test in diet-induced-obese mice

Presented as Poster-340 at ObesityWeek 2026, the study evaluated subcutaneous DD18 in mice with diet-induced obesity. The experiments included a 30-day comparison of DD18, semaglutide and the two drugs in combination.

A detailed account of the poster says DD18 alone reduced body weight and food intake. Body-composition analysis indicated lower fat mass alongside higher lean body mass. In mice receiving DD18 plus semaglutide, weight and fat loss exceeded that seen with semaglutide alone, while the reduction in fat-free mass was smaller.

That combination result is potentially significant because it suggests DD18 may do more than duplicate the weight-lowering effect of an existing therapy. A drug that produces a greater proportion of weight loss from fat, while limiting losses from other tissues, could offer a different treatment profile. But this remains a hypothesis generated in an animal model, not a demonstrated clinical advantage.

The study did not provide human evidence about efficacy, tolerability or how durable the body-composition changes might be. Conference-poster findings also provide a more limited basis for evaluation than a full peer-reviewed account with complete methods and data.

Why the composition of weight loss matters

Body weight combines fat, muscle, organs, bone and water into a single number. Two people—or two treatment groups—can therefore lose the same amount of weight while experiencing materially different changes in body composition.

This issue is already relevant to current incretin-based medicines. A 2026 review of body-composition evidence concluded that semaglutide and tirzepatide generally reduce fat mass preferentially, but also produce smaller, consistent reductions in lean mass or lean soft tissue. That does not mean all measured lean-tissue loss is skeletal muscle, nor that every reduction has the same clinical significance.

Common body-composition technologies such as dual-energy X-ray absorptiometry and bioelectrical impedance analysis estimate lean tissue rather than measuring skeletal muscle directly. Their lean-mass categories can include organs and body water. Hydration changes during weight loss can consequently shift the reading without representing a comparable change in contractile muscle tissue.

For DD18, the reported rise or preservation in mouse lean mass is therefore best treated as a promising composition signal. It is not yet evidence of muscle growth or protection in people.

A mechanism outside the GLP-1 pathway

D&D describes DD18 as an agonist of urocortin-2, or UCN2, giving it a mechanism distinct from marketed GLP-1-based treatments. The reduction in food intake seen in the mouse experiments indicates that altered energy intake may contribute to the observed weight loss, although the reported results do not establish how much of the body-composition effect came from appetite, energy use or other physiological changes.

The stronger result with DD18 and semaglutide together creates a rationale for studying complementary action. Semaglutide alone already tends to produce substantially more fat loss than lean-tissue loss; the relevant question is whether another agent can shift that balance further without undermining safety or function.

An enhanced result in mice does not by itself prove pharmacological synergy, however. Nor does it determine whether an effective human dose of DD18 could be combined safely with a GLP-1 medicine. Those questions require controlled clinical studies with each drug alone and in combination.

From a lean-mass reading to functional evidence

The reported DD18 programme included a wire-hang test in mice, indicating an effort to assess performance as well as body composition. Functional testing is important because maintaining a lean-mass estimate is not necessarily the same as maintaining strength or physical capability.

Human studies would need to connect several layers of evidence: overall weight and fat loss, direct or validated measures of skeletal muscle, and outcomes such as strength or physical performance. Tracking these measures over time would help determine whether any apparent muscle protection persists during treatment and after weight stabilizes.

This distinction also matters when interpreting a reported increase in lean mass. Because the category includes water and organs, a higher value cannot be translated directly into newly formed skeletal muscle. The mouse result supports further investigation of DD18’s effects on tissue composition; it does not establish a muscle-building effect.

An early entrant in the body-composition race

DD18 joins a wider effort to improve the quality, rather than simply the quantity, of pharmacological weight loss. A separate 2026 review of lean-mass-preservation strategies found that most drug approaches in this area remain at an early research stage. Those programmes include agents directed at activin, growth-hormone and androgen-receptor pathways, although DD18 targets a different system and cannot be compared directly on the available evidence.

For clinicians and health-literate readers, the practical significance is not that an alternative to established obesity medicines is close at hand. It is that body composition is becoming a deliberate drug-development objective. The DD18 mouse findings provide an encouraging early signal: fat mass fell, measured lean mass was maintained or increased, and combination treatment outperformed semaglutide alone on reported weight and composition measures.

Whether that pattern can be reproduced safely in people—and shown to preserve actual muscle and function—will determine whether DD18 represents a meaningful advance rather than an interesting preclinical result.